FDAsafety guidance66% confidence
FDA Approves First Generics of Gilotrif (afatinib) Tablets
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Novo Nordisk; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Endocrinology · Obesity
- Sub-indication
- General
Related signal: FDA Accepts Supplement for SAXENDA (Liraglutide) by Novo